.INVESTIGATION HIGHLIGHT.06 August 2024.
A large randomized regulated trial with cisgender females highlights the problems of fidelity to a day-to-day oral preexposure treatment program and also demonstrates that twice-yearly injection of lenacapavir may maintain helpful HIV deterrence degrees over 6 months.